Oxford BioMedica PLC OXB.GB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 714
- Website
- https://www.oxb.com
Comparables
Valuation
|
Metric
|
OXB.GB
|
ZURA
|
AVCT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 2.59 | 6.87 |
Price/Sales | — | — | 6.16 |
Price/Cash Flow | — | — | — |
Price/Earnings
OXB.GB
ZURA
AVCT
Financial Strength
|
Metric
|
OXB.GB
|
ZURA
|
AVCT
|
|---|---|---|---|
Quick Ratio | 2.80 | 6.12 | 0.53 |
Current Ratio | 3.19 | 6.17 | 0.62 |
Interest Coverage | −16.27 | — | −0.90 |
Quick Ratio
OXB.GB
ZURA
AVCT
Profitability
|
Metric
|
OXB.GB
|
ZURA
|
AVCT
|
|---|---|---|---|
Return on Assets (Normalized) | −22.80% | −53.80% | −39.86% |
Return on Equity (Normalized) | −56.31% | −87.06% | −154.75% |
Return on Invested Capital (Normalized) | −27.66% | −66.21% | −50.93% |
Return on Assets
OXB.GB
ZURA
AVCT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Bvvmfygjv | Lyc | $644.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cqgkwgfb | Lxgkvjn | $121.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Wchpfrmb | Yzdvn | $116.5 Bil | |||
| Moderna Inc
MRNA
| Pyywtnkz | Vqtnf | $44.4 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zvbndqmf | Mqylk | $30.8 Bil | |||
| argenx SE ADR
ARGX
| Zzmkhstm | Rlgs | $25.7 Bil | |||
| BioNTech SE ADR
BNTX
| Vkydfgp | Vtsc | $19.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gmdtbpnd | Mrvwvp | $15.6 Bil | |||
| United Therapeutics Corp
UTHR
| Bksxprz | Lkybk | $14.2 Bil | |||
| Incyte Corp
INCY
| Psgzxtlb | Bswdjl | $12.0 Bil |